(Q34424790)

2 August 2017

1 reference

title

Second‐line chemotherapy for non‐small cell lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

1 reference

Xavier Bonfill Cosp

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

Consol Serra

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

Montse Sacristan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

Miquel Nogué

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

Ferran Losa

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

Jesús Montesinos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

language of work or name

English

0 references

publication date

1 January 2001

1 reference

PubMed ID

11687161

Cochrane Database of Systematic Reviews

2 August 2017

2002

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

volume

2002

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

page(s)

CD002804

1 reference

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

2 August 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Vinorelbine-based regimens as salvage treatment in patients with advanced non-small cell lung cancer: two parallel multicenter phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Docetaxel and granulocyte colony-stimulating factor in patients with advanced non-small-cell lung cancer previously treated with platinum-based chemotherapy: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Benefits of polychemotherapy in advanced non-small-cell bronchogenic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Therapeutic efficacy and pharmacokinetics of vindesine and vindesine-cisplatin in previously treated patients with non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Carboplatin and paclitaxel for previously treated patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Second-line chemotherapy for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Chemotherapy versus palliative care in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002804

10.1002/14651858.CD002804

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6993946&resulttype=core&format=json

14 May 2020

1 reference